ALK-Abello A/S 2009 AR2
The report highlights ALK's financial and operational performance for the fiscal year 2009, during which the company achieved 10% organic growth in allergy vaccine sales and a 47% increase in operating profit. Key milestones included the European approval of GRAZAX as a disease-modifying therapy and successful clinical trials in the USA. In terms of corporate social responsibility, ALK focused on safety, health, and environment (SHE), establishing a long-term strategy to reduce CO2 emissions by 15% or more by 2014 compared to 2008. The company also completed significant investments in new tablet production facilities and launched a global management training programme.
Company: ALK-Abello A/S
Sector: Manufacturing
Country: Denmark
Year: 2009
Type: AR2
Pages: 78
Back to company
ALK-Abello A/S
Annual Report
The report highlights ALK's financial and operational performance for the fiscal year 2009, during which the company achieved 10% organic growth in allergy vaccine sales and a 47% increase in operating profit. Key milestones included the European approval of GRAZAX as a disease-modifying therapy and successful clinical trials in the USA. In terms of corporate social responsibility, ALK focused on safety, health, and environment (SHE), establishing a long-term strategy to reduce CO2 emissions by 15% or more by 2014 compared to 2008. The company also completed significant investments in new tablet production facilities and launched a global management training programme.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2009
Reporting Period
Jan 1, 2009 - Dec 31, 2009
Fiscal Year
2009
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees